43% Pharma marketers prefer programmatic messaging platforms in India
Amid the chaos recurring waves of the pandemic have created, pharma marketers are shifting their focus to newer and innovative solutions to engage Physicians, apparent from the phenomenal rise in programmatic messaging technologies.
As the latest report by Doceree, the first global network of physician-only platforms for programmatic messaging, suggests around 43% of pharma marketers in India now prefer programmatic messaging platforms to reach out to physicians, utilizing its ability to segment healthcare experts and align their communication for optimization and better business outcomes.
To understand how programmatic is evolving, Doceree delved into inventory and campaign behavior trends of its multiple partners, studying over 1,100 campaigns. These were run on a mix of 165 physician-only publisher platforms via Doceree by 102 advertisers - consisting of consumer healthcare and medical devices companies, life sciences brands, hospitals, and diagnostics, covering 100+ specialties.
The report - ‘Programmatic Trends in Pharma HCP Marketing 2022’ – points that pharma’s digital ad spending has risen considerably worldwide and the trend is expected to grow further on the back of programmatic fueling its growth.
“The trend looks promising as we see pharma brands earmarking a significant budget to programmatic marketing,” said Harshit Jain MD, Founder & Global CEO, Doceree. “We are seeing 5 out of ten dollars spent on digital being set aside for programmatic messaging.”
Besides, the report captures popular trends that are shaping the programmatic pharma physician marketing space:
1. Programmatic gains prominence among endemic publishers
In 2021, there was a jump up to 53% in the exposed programmatic inventory of endemic publishers - HCP-only digital platforms such as medical education sites, HCP networking sites, medical associations, and medical journals that HCPs visit to advance their professional knowledge or to connect with their peer group - on the back of their partnership with specialized ad exchanges.
2. First party data makes contextual marketing valuable
Piqued interest of pharma brands in first party data and significant surge in performance campaigns on endemic walled-garden, and point of care platforms – e-prescribing (eRx), telehealth, and electronic health record (EHR) platforms - where data is collected directly from the physicians via log-ins. There has been a 39% year-on-year increase in the usage of such platforms.
3. Big opportunity in physician’s clinical workflow
Point-of-care networks are valuable assets for pharma marketers to enrich communications during a physician’s workflow - from lab test to the stage of diagnosis going to the point of writing a prescription - and deliver informative messages at decision-making moments while they are in a professional mindset.
Further, 29% of marketers globally are mulling boosting budgets for trigger-based campaigns on Point of Care channels as they are in dialogue with partners for planning and activation.
4. Account-based marketing creates a buzz
Brands are eager to keep up their spending across secondary-based institutions like hospitals, nursing homes and research institutes going into 2022 when targeting physicians of a particular specialty.
The data analysis of the report disclosed a 135% increase in spending on account-based campaigns by brand marketers handling medical devices in 2021 over the previous year.
“When executed properly, programmatic is a powerful tool to bring targeted scale for pharma marketers,” adds Jain. “For publishers, it offers promise to align relevant messaging and platform experience for physicians visiting the respective sites.”